Marlène Vonarx

  • Citations Per Year
Learn More
To report three cases of bullous pemphigoid in patients treated with vildagliptin. Case 1: An 86-year-old woman presented with bullous pemphigoid after 1 month of treatment with vildagliptin and metformin. After introduction of clobetasol, the symptoms resolved although vildagliptin was continued. However, the skin lesions reappeared 3 months later.(More)
The reaction catalyzed by IMP dehydrogenase (IMP: NAD+ oxidoreductase EC 1.2.1.14) from Aerobacter aerogenes has been investigated kinetically at pH 8.1 as a three reactant system by means of steady-state velocity studies in the absence of products, as well as by inhibition studies using products and substrate analogues. The mechanism appears to be a(More)
BACKGROUND Few data are available concerning the efficiency of pulse corticosteroids in alopecia areata (AA). OBJECTIVE Our purpose was to assess the long-term outcomes of patients treated with methylprednisolone bolus. METHODS This study included 60 patients treated between 1995 and 2000. The short-term outcomes were analyzed in 2000. The long-term(More)
BACKGROUND Specific cutaneous infiltrates of chronic lymphocytic leukaemia (CLL) are rare. They occur after a mean disease duration of 3 years. CLL skin infiltrates as the primary manifestation of the disease have been reported, but a normal lymphocyte count at diagnosis is rare. We present two cases of CLL initially presenting in the skin, without(More)
BP: Bullous pemphigoid TNF-a: tumor necrosis factor-alfa INTRODUCTION Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by antietumor necrosis factor-alfa (TNF-a) agents has been described in the literature. No cases have been(More)
  • 1